Atrial Fibrillation

Afib medication decision tool

Select rate or rhythm control, then enter the key clinical features. This tool suggests a practical agent and common adult dosing.

Recommendation will appear here

Use this as a bedside decision aid, not a substitute for patient-specific clinical judgment.

Core Approach

  • Assess stability
    • Unstable: synchronized cardioversion
    • Stable: rate/rhythm strategy + stroke prevention
    • Do not delay cardioversion for anticoagulation if unstable
  • Assess stroke risk
    • Anticoagulation is based on CHA₂DS₂-VASc, not Afib pattern
    • Paroxysmal Afib still counts
    • Aspirin is not adequate stroke prevention
  • Choose rate vs rhythm control
    • Rate control reasonable for older/minimally symptomatic patients
    • Rhythm control favored if symptomatic, younger, recent diagnosis, HF, difficult rate control, or suspected Afib-mediated cardiomyopathy
  • Treat substrate
    • HTN, obesity, OSA, alcohol, HF, diabetes, thyroid disease, stimulants

Initial evaluation

  • Confirm diagnosis
    • 12-lead EKG
    • Irregularly irregular rhythm
    • No organized atrial activity
  • Initial workup
    • EKG
    • TTE
    • CBC
    • CMP/Mg
    • TSH
    • Troponin only if ischemic symptoms, concerning ECG, or high-risk presentation
    • BNP if HF/dyspnea phenotype unclear
    • Ambulatory monitor if burden or symptom-rhythm correlation needed
  • Key questions
    • How long has patient been in Afib?
    • First episode or recurrent?
    • Is Afib causing instability, HF, ischemia, or cardiomyopathy?
    • What is CHA₂DS₂-VASc?
    • Is rate control enough?

Acute management

  • Unstable Afib
    • Shock, hypotension, pulmonary edema, ongoing ischemia, AMS, severe decompensated HF
    • Immediate synchronized cardioversion
    • Anticoagulate afterward if stroke risk warrants
    • Evaluate trigger after stabilization
  • Stable Afib with RVR
    • EF preserved: beta blocker, diltiazem, or verapamil
    • HFrEF: beta blocker if tolerated, digoxin if low BP, amiodarone if refractory/critically ill
    • Avoid diltiazem/verapamil in significant LV dysfunction
    • Decompensated HF: digoxin or IV amiodarone depending on acuity
    • Critical illness/sepsis: treat trigger, then beta blocker/amiodarone/digoxin depending on BP/EF
  • Pre-excited Afib
    • Stable: procainamide
    • Unstable: synchronized cardioversion
    • Avoid AV nodal blockers

Anticoagulation

  • High risk
    • Men CHA₂DS₂-VASc ≥2
    • Women CHA₂DS₂-VASc ≥3
    • Anticoagulation recommended
  • Intermediate risk
    • Men 1
    • Women 2
    • Consider anticoagulation using risk modifiers/shared decision-making
  • Low risk
    • Men 0
    • Women 1 from sex alone
    • No anticoagulation for Afib stroke prevention

Combined CHA₂DS₂-VASc and HAS-BLED Calculator

Estimate stroke risk and bleeding risk in atrial fibrillation

CHA₂DS₂-VASc

Stroke risk assessment for atrial fibrillation

Age
Sex
CHF history
Hypertension history
Stroke/TIA/thromboembolism history
Vascular disease history
Diabetes history

HAS-BLED

Major bleeding risk assessment

Hypertension
Abnormal liver/kidney function
Stroke history
Bleeding history
Labile INRs
Elderly ≥65 years
Drugs/alcohol

CHA₂DS₂-VASc Score

0
Complete selections to calculate stroke risk.

HAS-BLED Score

0
Complete selections to calculate bleeding risk.
Make selections, then click Calculate.
HAS-BLED should not be used alone to deny anticoagulation. Use it to identify modifiable bleeding risks.
```

Anticoagulant choice

Afib anticoagulation medication choice and dosing
DOACs are preferred for most patients with nonvalvular Afib. Warfarin is preferred for mechanical valves and moderate-to-severe rheumatic mitral stenosis.
Medication Standard dose Dose reduction Key note
Preferred strategy DOAC preferred Use labeled dose-reduction criteria DOACs for most patients. Use warfarin for mechanical valves or moderate-to-severe rheumatic mitral stenosis.
apixaban 5 mg BID 2.5 mg BID if 2 of 3:
age ≥80
weight ≤60 kg
Cr ≥1.5 		Often favored in CKD/older patients when otherwise appropriate.
rivaroxaban 20 mg daily with food 15 mg daily with food if CrCl 15-50 Must be taken with food for absorption.
dabigatran 150 mg BID if CrCl >30 75 mg BID if CrCl 15-30 Higher GI side-effect burden; avoid if renal function is too low.
edoxaban 60 mg daily 30 mg daily if CrCl 15-50, weight ≤60 kg, or selected P-gp inhibitors Less commonly used than apixaban/rivaroxaban in many practices.
warfarin Individualized dosing to INR goal Adjust based on INR Preferred for mechanical valves and moderate-to-severe rheumatic mitral stenosis.
Dosing note: Do not underdose DOACs unless dose-reduction criteria are met.

Rate vs rhythm control

  • Rate control favored when
    • Minimal symptoms
    • Older/frail patient
    • Long-standing Afib
    • Severe LA enlargement
    • Low chance of durable sinus rhythm
    • Patient preference
    • Failed rhythm-control attempts
  • Rate control agents
    • Beta blocker: good for CAD, HTN, adrenergic states
    • Diltiazem/verapamil: effective if EF preserved; avoid in HFrEF/decompensated HF
    • Digoxin: useful in HFrEF or low BP; less effective in high catecholamine states
    • Amiodarone: critically ill, decompensated HF, refractory RVR; may cardiovert
  • Rate target
    • Resting HR <100-110 reasonable if asymptomatic and LV function preserved
    • Use stricter target if symptoms, HF, tachycardia-mediated cardiomyopathy, or CRT pacing issues
  • Rhythm control favored when
    • Persistent symptoms despite rate control
    • New or recently diagnosed Afib
    • Younger patient
    • HFrEF or suspected Afib-mediated cardiomyopathy
    • Difficult rate control
    • High Afib burden
    • Need to preserve CRT pacing
    • Patient preference
  • Rhythm control options
    • Electrical cardioversion
    • Antiarrhythmic drug therapy
    • Catheter ablation

Cardioversion

  • Indications
    • Unstable Afib
    • Ongoing symptoms despite rate control
    • Decompensated HF due to Afib
    • Ischemia due to Afib
    • Failure of rate control
    • Rhythm-control strategy selected
  • Anticoagulation
    • Afib ≥48 hr or unknown duration: anticoagulate ≥3 wks before cardioversion OR obtain TEE/CT to exclude LAA thrombus
    • Continue anticoagulation ≥4 wks after cardioversion
    • Long-term anticoagulation depends on CHA₂DS₂-VASc, not sinus rhythm maintenance

Antiarrhythmic selection

  • No significant structural heart disease
    • Flecainide
    • Propafenone
    • Dronedarone
    • Sotalol
    • Dofetilide
    • Amiodarone
  • CAD/prior MI
    • Dronedarone
    • Dofetilide
    • Sotalol
    • Amiodarone
    • Avoid flecainide/propafenone
  • HFrEF
    • Amiodarone
    • Dofetilide
    • Avoid flecainide, propafenone, dronedarone in recent decompensated/advanced HF
    • Sotalol generally avoided/cautious
  • Key notes
    • Class IC agents need AV nodal blocker
    • Dofetilide requires inpatient initiation
    • Sotalol requires QT/renal monitoring
    • Amiodarone is effective but toxic long-term
    • Amiodarone can cardiovert, so anticoagulation context matters
Afib rate and rhythm control medications
Doses below are typical adult starting/maintenance doses. Adjust for renal function, QTc, BP, EF, drug interactions, and inpatient vs outpatient setting.
Strategy Medication Usual dosing Best use Avoid / caution
Rate control
Rate metoprolol tartrate PO: 12.5–50 mg q6–12h
IV: 2.5–5 mg q5 min up to 15 mg 		Good first-line option for stable Afib with RVR, CAD, HTN, adrenergic states Caution in hypotension, bradycardia, severe bronchospasm, decompensated HF
Rate metoprolol succinate PO: 25–200 mg daily Chronic outpatient rate control; preferred beta blocker option in HFrEF Not ideal for rapid inpatient titration compared with tartrate
Rate carvedilol PO: 3.125–25 mg BID Chronic rate control in HFrEF, HTN, cardiomyopathy More BP-lowering than metoprolol; caution in hypotension
Rate diltiazem IV bolus: 0.25 mg/kg, then 0.35 mg/kg if needed
IV drip: 5–15 mg/hr
PO IR: 30–90 mg q6h
PO ER: 120–360 mg daily 		Effective for stable Afib with RVR when EF is preserved Avoid in decompensated HFrEF/significant LV dysfunction; caution hypotension/bradycardia
Rate verapamil PO IR: 40–80 mg TID
PO ER: 120–360 mg daily 		Alternative AV nodal blocker when EF preserved Avoid in HFrEF/decompensated HF; constipation, hypotension, bradycardia
Rate digoxin Load: 0.25 mg IV/PO q6h to total 0.75–1 mg
Maintenance: 0.125–0.25 mg daily 		Useful when BP is soft or in HFrEF; adjunct when beta blocker/CCB limited Renal dosing; monitor level; less effective in sepsis/high catecholamine states
Rate amiodarone IV: 150 mg over 10 min, then 1 mg/min x6h, then 0.5 mg/min
PO load: often 400 mg BID/TID to total 6–10 g, then 100–200 mg daily 		Critically ill, decompensated HF, refractory RVR, rhythm-control overlap Can cardiovert; consider anticoagulation context. Long-term thyroid, liver, lung, ocular toxicity
Rhythm control / antiarrhythmic drugs
Rhythm flecainide PO: 50–150 mg BID
Pill-in-pocket: 200–300 mg once in selected patients 		No significant structural heart disease; paroxysmal Afib; pill-in-pocket after monitored trial Avoid CAD/prior MI, LV dysfunction, significant structural heart disease. Use with AV nodal blocker
Rhythm propafenone PO IR: 150–300 mg q8h
PO ER: 225–425 mg BID
Pill-in-pocket: 450–600 mg once in selected patients 		No significant structural heart disease; paroxysmal Afib; pill-in-pocket after monitored trial Avoid CAD/prior MI, LV dysfunction, significant structural heart disease. Use with AV nodal blocker
Rhythm dronedarone PO: 400 mg BID with meals Maintenance of sinus rhythm in selected patients without advanced/recently decompensated HF Avoid permanent Afib, recent decompensated HF, advanced HFrEF; monitor liver/drug interactions
Rhythm sotalol PO: 80–160 mg BID Rhythm maintenance when QT and renal function acceptable Renal dosing; QT monitoring; avoid prolonged QT, significant renal dysfunction, bradycardia; caution HFrEF
Rhythm dofetilide PO: 125–500 mcg BID based on CrCl/QTc Rhythm maintenance; can be used in HFrEF with appropriate monitoring Requires inpatient initiation/re-initiation with QT and renal monitoring
Rhythm amiodarone PO load: 400 mg BID/TID to total 6–10 g
Maintenance: 100–200 mg daily
IV: 150 mg over 10 min, then infusion 		Most effective AAD; useful in HFrEF, CAD, refractory Afib, critically ill patients Long-term toxicity: thyroid, liver, lung, ocular, skin, neuro; many drug interactions
Rhythm ibutilide IV: 1 mg over 10 min; may repeat once
If <60 kg: 0.01 mg/kg 		Pharmacologic cardioversion of Afib/flutter in monitored setting QT prolongation/torsades risk; continuous ECG monitoring; correct K/Mg first

Catheter ablation

  • Consider for
    • Symptomatic Afib despite AADs
    • AADs contraindicated, ineffective, or not tolerated
    • Patient preference to avoid long-term AADs
    • Selected first-line rhythm control, especially younger symptomatic paroxysmal Afib
    • Suspected Afib-mediated cardiomyopathy
    • HFrEF with symptomatic Afib
    • Inadequate rate control
    • Afib limiting CRT delivery
  • Best candidates
    • Paroxysmal Afib
    • Shorter Afib duration
    • Smaller LA
    • Fewer comorbidities
    • Younger age
  • Post-ablation
    • Continue anticoagulation based on CHA₂DS₂-VASc
    • Do not stop OAC solely because rhythm appears controlled

AV node ablation and pacing

  • Consider when
    • Rate control fails
    • Rhythm control fails or is not appropriate
    • Medication intolerance
    • Need to guarantee BiV pacing in CRT patients
  • Key point
    • Creates pacemaker dependence
    • Consider CRT or conduction-system pacing if reduced EF or high pacing burden

Left atrial appendage occlusion

  • Consider when
    • Elevated stroke risk
    • Contraindication to long-term OAC
    • Recurrent major bleeding
    • Nonreversible bleeding risk
  • Not ideal when
    • Patient tolerates DOAC
    • Low CHA₂DS₂-VASc
    • Bleeding risk is reversible
    • Patient simply prefers no anticoagulation

Afib with heart failure

  • Key question
    • Is Afib a bystander, trigger, or driver of HF?
  • Suspect Afib-mediated cardiomyopathy when
    • New LV dysfunction with persistent Afib/RVR
    • High Afib burden
    • Poor rate control
    • No other clear cause
    • EF improves after rhythm/rate control
  • HFrEF
    • Avoid diltiazem/verapamil
    • Use HF beta blocker if tolerated
    • Digoxin if low BP
    • Amiodarone or dofetilide for rhythm control
    • Consider ablation early if symptomatic or Afib-mediated cardiomyopathy suspected
  • HFpEF
    • Rate control reasonable
    • Consider rhythm control if symptoms/congestion track with Afib

Afib during acute illness

  • Common triggers
    • Sepsis
    • Pneumonia
    • PE
    • Post-op state
    • ACS
    • Decompensated HF
    • Critical illness
  • Management
    • Treat trigger
    • Rate control if stable
    • Cardiovert if unstable
    • Reassess stroke risk before discharge
    • Arrange rhythm follow-up
    • Do not dismiss acute-illness Afib as automatically benign or transient

Pre-excited Afib

  • Clues
    • Irregular wide-complex tachycardia
    • Very rapid rates
    • Beat-to-beat QRS variation
    • Known/suspected accessory pathway
  • Use
    • Procainamide if stable
    • Synchronized cardioversion if unstable
  • Avoid
    • Beta blockers
    • Diltiazem/verapamil
    • Digoxin
    • Adenosine
    • AV nodal blocker monotherapy
    • AV nodal blockade can precipitate VF

References

  1. Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., Gorenek, B., Hess, P. L., Hlatky, M., Hogan, G., Ibeh, C., Indik, J. H., Kido, K., Kusumoto, F., Link, M. S., ... Peer Review Committee Members. (2024). 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation. Circulation, 149(1), e1–e156. https://doi.org/10.1161/CIR.0000000000001193
  2. Van Gelder, I. C., Rienstra, M., Bunting, K. V., Casado-Arroyo, R., Caso, V., Crijns, H. J. G. M., De Potter, T. J. R., Dwight, J., Guasti, L., Hanke, T., Jaarsma, T., Lettino, M., Lowres, N., Metzner, A., Milicic, D., Potpara, T. S., Raatikainen, P., Richter, D. J., Romiti, G. F., ... ESC Scientific Document Group. (2024). 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery. European Heart Journal, 45(36), 3314–3414. https://doi.org/10.1093/eurheartj/ehae176
  3. Lip, G. Y. H., Nieuwlaat, R., Pisters, R., Lane, D. A., & Crijns, H. J. G. M. (2010). Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation. Chest, 137(2), 263–272. https://doi.org/10.1378/chest.09-1584
  4. Pisters, R., Lane, D. A., Nieuwlaat, R., de Vos, C. B., Crijns, H. J. G. M., & Lip, G. Y. H. (2010). A novel user-friendly score to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest, 138(5), 1093–1100. https://doi.org/10.1378/chest.10-0134
  5. Wyse, D. G., Waldo, A. L., DiMarco, J. P., Domanski, M. J., Rosenberg, Y., Schron, E. B., Kellen, J. C., Greene, H. L., Mickel, M. C., Dalquist, J. E., & Corley, S. D. (2002). A comparison of rate control and rhythm control in patients with atrial fibrillation. The New England Journal of Medicine, 347(23), 1825–1833. https://doi.org/10.1056/NEJMoa021328
  6. Kirchhof, P., Camm, A. J., Goette, A., Brandes, A., Eckardt, L., Elvan, A., Fetsch, T., van Gelder, I. C., Haase, D., Haegeli, L. M., Hamann, F., Heidbuchel, H., Hindricks, G., Kautzner, J., Kuck, K. H., Mont, L., Ng, G. A., Rekosz, J., Schoen, N., ... Breithardt, G. (2020). Early rhythm-control therapy in patients with atrial fibrillation. The New England Journal of Medicine, 383(14), 1305–1316. https://doi.org/10.1056/NEJMoa2019422
  7. Marrouche, N. F., Brachmann, J., Andresen, D., Siebels, J., Boersma, L., Jordaens, L., Merkely, B., Pokushalov, E., Sanders, P., Proff, J., Schunkert, H., Christ, H., Vogt, J., & Bänsch, D. (2018). Catheter ablation for atrial fibrillation with heart failure. The New England Journal of Medicine, 378(5), 417–427. https://doi.org/10.1056/NEJMoa1707855